Brazil’s health regulator greenlights trials of new Chinese vaccine

RIO DE JANEIRO, BRAZIL – Brazilian health regulator Anvisa has authorized clinical trials of a new Covid vaccine developed by China’s Sichuan Clover Biopharmaceuticals, according to a statement on Monday April 19.

Anvisa said the company was authorized to conduct Phase II and III trials in Brazil. Sichuan Clover is planning to test the vaccine on 22,000 volunteers in Latin America, South Africa, Belgium, China, Spain, Poland and United Kingdom.

Related coverage: Indigenous peoples use technology to keep language and culture alive · Hidrovias do Brasil buys shipping companies from Imperial group · Investments in startups that combine technology and market in Brazil approach US$1 billion · Business travel will not return to pre-pandemic level

More: Brazil news in English, every day from The Rio Times.

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

Brazil runoff, Sunday, October 25: When is the Brazil runoff election. Latest: Brazil runoff polls, Flávio 51%, Lula 49%.